Comparison between Integris Medtech IPO and Runwal Developers IPO.
Integris Medtech IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Runwal Developers IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Integris Medtech IPO is up to ₹0.00 Cr whereas the issue size of the Runwal Developers IPO is up to ₹2,000.00 Cr. The final issue price of Integris Medtech IPO is and of Runwal Developers IPO is .
| Integris Medtech IPO | Runwal Developers IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹925.00 Cr | up to ₹1,700.00 Cr |
| OFS Issue Size | 2,16,74,531 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹300.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹2,000.00 Cr |
Integris Medtech IPO opens on , while Runwal Developers IPO opens on . The closing date of Integris Medtech IPO and Runwal Developers IPO is , and , respectively.
Integris Medtech IPO P/E ratio is , as compared to Runwal Developers IPO P/E ratio of .
| Integris Medtech IPO | Runwal Developers IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Integris Medtech Ltd.'s revenue increased by 24% and profit after tax (PAT) rose by 1547% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Runwal Developers Ltd.'s revenue increased by 104% and profit after tax (PAT) dropped by 89% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 83.24 | 99.15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 5.35% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 14.51% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.98 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.52 | ₹3.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 1.48% | 5.32% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Integris Medtech IPO Retail Individual Investors (RII) are offered 0 shares while in Runwal Developers IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Integris Medtech IPO and 0 shares in Runwal Developers IPO.
| Integris Medtech IPO | Runwal Developers IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Integris Medtech IPO subscribed in total, whereas Runwal Developers IPO subscribed .
